Kidney renal clear cell carcinoma (KIRC) is a metabolically and immunologically complex cancer known for its ability to evade the immune system and resist conventional treatments. Understanding the molecular mechanisms that allow KIRC tumors to hide from immune cells is critical for developing more effective therapies.
One underexplored mechanism involves ribosome biogenesis (RiboSis), the cellular process of producing ribosomes, which are the molecular machines that make all proteins. Cancer cells often ramp up ribosome production to fuel their rapid growth. This study investigated how abnormal RiboSis shapes the tumor environment in KIRC and influences how patients respond to treatment.
The tumor microenvironment (TME) in KIRC contains a complex mixture of immune cells, blood vessel cells, and structural support cells that collectively determine whether the immune system can attack the tumor or is suppressed. Genes related to RiboSis may alter this environment in ways that make tumors more aggressive or treatment-resistant.
Using large-scale genomic data and advanced machine learning, the researchers set out to identify specific genes within RiboSis-related networks that could serve as biomarkers for predicting patient survival and guiding immunotherapy decisions. Their analysis ultimately focused on a gene called PTGER4.
The study integrated multiple large genomic datasets, including single-cell RNA sequencing (scRNA-seq) data and bulk transcriptomic data from TCGA, GTEx, and the International Cancer Genome Consortium. Single-cell data allows researchers to examine gene activity in individual cells rather than averaging across entire tumors, revealing important cellular heterogeneity.
A gene network analysis method called hdWGCNA (high-dimensional weighted gene co-expression network analysis) was applied to the single-cell data to identify groups of genes that work together in kidney cancer cells. This approach identified a specific gene module, the yellow module, that was most strongly associated with RiboSis activity.
Patients were then clustered into two RiboSis-based molecular subtypes using the PAM (Partitioning Around Medoids) algorithm. This statistical approach groups patients based on similarities in their RiboSis gene expression patterns, creating clinically meaningful subgroups with distinct survival outcomes.
To identify the most important prognostic gene from within these RiboSis networks, two machine learning approaches were applied in parallel: CoxBoost, which identifies genes that best predict survival while penalizing unnecessary variables, and Random Survival Forest, which ranks genes by how much they improve survival prediction. Both methods converged on PTGER4 as the most critical gene.
The analysis identified two distinct KIRC molecular subtypes based on RiboSis activity. Patients in Pattern 1 had significantly longer survival compared to Pattern 2, with a highly statistically significant difference (p-value less than 0.0001). This confirms that ribosome production patterns are clinically meaningful in kidney cancer.
PTGER4, a gene encoding a receptor for prostaglandin E2, emerged as the most powerful prognostic biomarker from the machine learning analysis. Higher PTGER4 expression was consistently associated with improved survival across three independent patient cohorts: TCGA-KIRC, E-MTAB-1980, and RECA-EU.
Strikingly, PTGER4 was significantly lower in cancer cells than in normal cells, as confirmed by single-cell sequencing analysis. This suggests that cancer cells actively suppress PTGER4 expression, perhaps to remove a natural brake on tumor growth and immune activation.
Tumors with high PTGER4 expression showed much higher levels of immune cell activity, including elevated CD8 T cells, dendritic cells, B cells, natural killer cells, and macrophages. All nine immunotherapy response determinants analyzed, including markers of immune cytolytic activity and T cell inflammation, were significantly higher in the PTGER4-high group, suggesting these patients may be better candidates for immunotherapy.
PTGER4 expression successfully predicted immunotherapy response with an AUC greater than 0.6 in six independent clinical cohorts studying different immune therapies, including anti-PD-1, anti-CTLA-4, and CAR-T cell therapies. While modest, this predictive power across diverse treatment types and patient populations is a promising signal of clinical utility.
Notably, PTGER4 was negatively correlated with immune checkpoint proteins such as PD-1 (PDCD1), CTLA4, and TIGIT. These are the targets of current checkpoint inhibitor therapies. Lower PTGER4 may mean more checkpoint expression, which allows cancer to shut down immune responses. Restoring PTGER4 could potentially counteract this immune suppression.
Drug sensitivity analysis identified 12 targeted therapy compounds that showed significantly greater effectiveness in PTGER4-high tumors. These included MEK inhibitors like Trametinib and BTK inhibitors like Ibrutinib. Patients with high PTGER4 expression may derive particular benefit from these specific therapies, while those with low PTGER4 may need alternative approaches.
Genomic analysis showed that high PTGER4 tumors had specific chromosomal mutations at regions including 1p36, a well-known tumor suppressor region. The co-occurrence of high PTGER4 and 1p36 deletion may represent a compensatory relationship where PTGER4 activation helps counterbalance the loss of other tumor suppressor genes.
To move beyond computational analysis, the researchers silenced the PTGER4 gene in kidney cancer cell lines using a technique called siRNA knockdown. This allowed them to observe what happens to cancer cells when PTGER4 function is reduced, mimicking the low-PTGER4 state seen in many patient tumors.
When PTGER4 was silenced, cancer cells showed a significant reduction in their ability to proliferate, as measured by both CCK-8 viability assays and EdU incorporation (a marker of DNA replication). Fewer cells were actively dividing, suggesting that PTGER4 normally limits tumor growth.
Silencing PTGER4 also significantly reduced the expression of MMP2 and MMP9, enzymes that help cancer cells break down barriers in surrounding tissue to spread to other organs. Additionally, the proliferation markers PCNA and Ki67 were also reduced, confirming that PTGER4 silencing broadly suppresses cancer cell activity.
Colony formation assays, which measure how many cancer cells can survive and form new colonies over time, showed significantly fewer colonies when PTGER4 was silenced. Taken together, these experiments provide direct experimental evidence that PTGER4 acts as a tumor suppressor, limiting kidney cancer cell growth, division, and invasive behavior.
This study establishes PTGER4 as a pivotal biomarker in KIRC with roles spanning prognosis prediction, immune modulation, and therapeutic sensitivity. It represents a significant step toward understanding how ribosome biogenesis dysregulation connects to immune evasion and treatment resistance in kidney cancer.
For patients and families, these findings suggest that measuring PTGER4 expression in tumor biopsies could one day help oncologists predict how a patient is likely to respond to immunotherapy or specific targeted drugs. This is exactly the kind of precision medicine approach that can make treatment more effective while reducing unnecessary side effects.
The pan-cancer analysis also revealed that PTGER4 functions as a protective factor in most cancer types beyond KIRC, suggesting its tumor-suppressive role is not unique to kidney cancer. This broadens the potential clinical significance of these findings across oncology.
Future studies need to validate PTGER4's predictive value prospectively in clinical trials, develop strategies for restoring or enhancing PTGER4 activity therapeutically, and explore whether PTGER4-targeting agents could be combined with existing checkpoint inhibitors to improve outcomes for kidney cancer patients.